Luton, Bedfordshire, United Kingdom, May 26, 2025 (GLOBE NEWSWIRE) -- Market Overview
Digital Therapeutics & Medical Devices Market Size and Growth
The global Digital Therapeutics & Medical Devices Market was valued at USD 7.88 billion in 2024 and is projected to reach USD 56.76 billion by 2034, growing at a CAGR of 21.65% during the forecast period.
Get a Sample PDF Brochure: https://exactitudeconsultancy.com/reports/44634/digital-therapeutics-medical-devices-for-migraine-market#request-a-sample
Digital Therapeutic Devices Market Insights
The digital therapeutic devices segment is also witnessing robust growth, with the market expected to expand from USD 4.86 billion in 2024 to USD 14.0 billion by 2035.
The Digital Therapeutics (DTx) market refers to the use of software-based interventions to prevent, manage, or treat medical disorders or diseases. These solutions are evidence-based, often prescribed by healthcare professionals, and delivered through apps, wearables, or connected platforms. DTx is distinct from general wellness apps due to its clinical validation and regulatory oversight.
The Medical Devices market includes all instruments, machines, implants, and software that are used for medical purposes, such as diagnosis, treatment, and patient monitoring. When merged with digital therapeutics, it creates a powerful ecosystem combining hardware, data analytics, AI, and user-centric care delivery.
Regional Analysis
North America
- Market Share: Held the largest share at 43.91% in 2024, attributed to advanced healthcare infrastructure and supportive regulatory policies.
Europe
- Market Dynamics: Countries like Germany, the UK, and France are leading due to robust healthcare systems and government initiatives promoting digital healthcare solutions.
Asia-Pacific
- Growth Potential: Expected to witness the fastest growth, driven by increasing healthcare digitization and a rising prevalence of chronic diseases.
Browse full Report - https://exactitudeconsultancy.com/reports/44634/digital-therapeutics-medical-devices-for-migraine-market
Key Therapeutic Areas
Diabetes Management
- Market Share: Dominated the digital therapeutics market with a 29.75% revenue share in 2024.
Mental Health
- Market Value: Valued at USD 1.5 billion in 2024, reflecting growing awareness and demand for digital interventions in mental health.
Cardiovascular Diseases
- Market Value: Estimated at USD 1.0 billion in 2024, with digital solutions aiding in managing heart-related ailments.
Key Market Players
Digital Therapeutics Companies (2025)
| No. | Company Name | Headquarters | Focus Areas |
| 1 | Omada Health | USA | Chronic disease management, AI-driven nutrition |
| 2 | Hinge Health | USA | Musculoskeletal care, AI-powered physical therapy |
| 3 | Sword Health | Portugal | Virtual physical therapy, AI integration |
| 4 | Click Therapeutics | USA | Prescription digital therapeutics for mental health |
| 5 | Kaia Health | Germany | AI-driven chronic pain management |
| 6 | DarioHealth | USA | Diabetes, hypertension, weight management |
| 7 | Virta Health | USA | Type 2 diabetes reversal |
| 8 | Pear Therapeutics | USA | Digital treatments for addiction and mental health |
| 9 | Big Health | USA | Mental health solutions, including insomnia and anxiety |
| 10 | Teladoc Health | USA | Telemedicine, chronic condition management |
| 11 | Lark Health | USA | AI-based chronic disease management |
| 12 | Maven Clinic | USA | Women's and family health |
| 13 | Talkspace | USA | Online therapy and mental health services |
| 14 | CureApp, Inc. | Japan | Mobile applications for chronic disease management |
| 15 | GAIA AG | Germany | Evidence-based therapeutic apps |
| 16 | Welldoc, Inc. | USA | Diabetes management through digital platforms |
| 17 | 2Morrow Inc. | USA | Smoking cessation and weight management |
| 18 | Reperio Health | USA | At-home health assessments |
| 19 | Thirty Madison | USA | Specialized virtual care for chronic conditions |
| 20 | Meru Health | USA | Digital mental health programs |
Buy Now : https://exactitudeconsultancy.com/purchase/?currency=USD&type=single_user_license&report_id=44634
Medical Device Companies (2025)
| No. | Company Name | Headquarters | Specialization |
| 1 | Medtronic | Ireland | Cardiovascular, diabetes, surgical devices |
| 2 | Johnson & Johnson | USA | Surgical instruments, implants, diagnostics |
| 3 | Abbott Laboratories | USA | Diabetes care, diagnostics, vascular devices |
| 4 | Siemens Healthineers | Germany | Imaging systems, laboratory diagnostics |
| 5 | GE Healthcare | USA | Imaging systems, medical devices, IT solutions |
| 6 | Philips Healthcare | Netherlands | Imaging systems, patient monitoring |
| 7 | Stryker Corporation | USA | Orthopedics, neurotechnology, surgical equipment |
| 8 | Boston Scientific | USA | Interventional cardiology, neuromodulation |
| 9 | Becton Dickinson (BD) | USA | Medical diagnostics, IV sets, syringes |
| 10 | Danaher Corporation | USA | Diagnostics, life sciences, dental equipment |
Recent Developments
1. Hinge Health's Successful IPO and AI Integration
In May 2025, Hinge Health, a digital physical therapy company, went public with a strong debut, reaching a $2.6 billion valuation. The company reported an 81% gross margin and $17.1 million profit in Q1 2025. Hinge Health utilizes AI-powered tools for motion tracking and care coordination, significantly reducing clinician hours and enhancing care delivery. The company plans to expand into additional healthcare specialties, further automating care with technology.
2. Medtronic's Diabetes Division Spin-Off
Medtronic announced plans to spin off its diabetes division into a standalone company. The new entity will be led by Que Dallara, current head of the diabetes division, and will employ around 8,000 people. This move aims to allow Medtronic to concentrate on its more lucrative businesses, especially heart devices. The separation is expected to be completed within 18 months.
3. Siemens Healthineers Faces Tariff Challenges
Siemens Healthineers' photon-counting CT scanner, the Naeotom Alpha, has gained global acclaim, including FDA approval. However, new U.S.-EU tariffs threaten to raise costs across the supply chain, affecting both foreign and domestic manufacturers. Industry leaders warn that these tariffs could raise healthcare costs, disrupt maintenance and supply, and stifle innovation.
4. FDA Approval of Intuitive Surgical's da Vinci 5 System
Intuitive Surgical received FDA clearance for its da Vinci 5 surgical system, which can be used in most surgical specialties, excluding cardiac and pediatric indications. This system, expected to enter full market launch in 2025, brings new capabilities of visualization, precision, and efficiency to operating rooms. The surgical robotics market is valued at over $8 billion in 2025 and is growing at a double-digit rate.
5. Empatica's Advancements in Wearable Health Monitoring
Empatica, a company specializing in AI-enabled tools for health monitoring, has developed medical-grade wearables like Embrace2 and EmbracePlus. These devices track physiological signals such as heart rate variability and skin temperature. Embrace2 has been cleared by the FDA as a seizure alerting solution for epilepsy patients. EmbracePlus is used for continuous health monitoring and has received the European CE mark as a Class IIa medical device.
6. Samsung's Noninvasive Glucose Monitoring Technology
Samsung has been developing noninvasive glucose monitoring technology using Raman spectroscopy. The company announced plans to incorporate glucose monitoring into its smartwatch, with a targeted release year of 2025. This technology aims to provide continuous glucose monitoring without the need for invasive procedures.
Technological Advancements
- Artificial Intelligence (AI): AI integration is enhancing personalization in digital therapeutics, enabling real-time feedback and tailored treatment plans.
- Wearable Devices: The proliferation of wearable health devices is facilitating continuous monitoring and data collection, improving patient engagement and outcomes.
Market Segmentation
By Product Type
- Software/Platforms: Expected to hold the largest market share due to increasing reliance on sophisticated solutions for therapeutic interventions.
- Devices: Includes wearable and non-wearable devices aiding in monitoring and treatment.
By Sales Channel
- Business-to-Business (B2B): Dominated the market with a 64.51% share in 2024, driven by adoption among healthcare providers and employers.
- Business-to-Consumer (B2C): Growing segment with direct-to-consumer apps and platforms.
This report is also available in the following languages : Japanese (片頭痛市場向けデジタル治療・医療機器), Korean (편두통 시장을 위한 디지털 치료제 및 의료 기기), Chinese (偏头痛市场的数字治疗和医疗设备), French (Thérapies numériques et dispositifs médicaux pour le marché de la migraine), German (Digitale Therapeutika und medizinische Geräte für den Migränemarkt), and Italian (Dispositivi medici e terapeutici digitali per il mercato dell'emicrania), etc.
Get a Sample PDF Brochure: https://exactitudeconsultancy.com/reports/44634/digital-therapeutics-medical-devices-for-migraine-market#request-a-sample
More Related Reports:
Dyschromia Therapeutics Market
The global dyschromia therapeutics market, valued at approximately $3.2 billion in 2024, is projected to reach around $5.3 billion by 2034. This represents a compound annual growth rate (CAGR) of about 5.3% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/51950/dyschromia-therapeutics-market
Alzheimer Therapeutics Market
The Alzheimer therapeutics market is valued at approximately $10 billion, reflecting a robust demand for innovative treatments in a rapidly aging population. The projected market value is anticipated to reach around $25 billion by 2034, driven by increasing prevalence rates and advancements in drug development. This results in a Compound Annual Growth Rate (CAGR) of approximately 9.5% during the forecast period of 2025-2034.
https://exactitudeconsultancy.com/reports/51928/alzheimer-therapeutics-market
Digital Therapeutics Market
The global digital therapeutics market is valued at approximately $6.9 billion in 2024, with projections estimating growth to about $17.6 billion by 2034. This translates to a robust compound annual growth rate (CAGR) of around 9.7% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/51885/digital-therapeutics-market
Central Nervo System Therapeutics Market
The global Central Nervous System (CNS) therapeutics market is valued at approximately $133 billion. This market is projected to reach around $194 billion by 2034, with an estimated Compound Annual Growth Rate (CAGR) of 3.7% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/51211/central-nervou-s-system-therapeutics-market
Acute Lymphoblastic Leukemia Therapeutics Market
The global market for Acute Lymphoblastic Leukemia (ALL) therapeutics is projected to reach approximately $12 billion by 2024, driven by rising cases and advances in treatment modalities. Over the forecast period from 2025 to 2034, this market is expected to expand robustly, with a projected Compound Annual Growth Rate (CAGR) of 8.5%. This growth is fueled by innovation in targeted therapies, including monoclonal antibodies and CAR T-cell therapies, which are improving patient outcomes and survival rates.
https://exactitudeconsultancy.com/reports/51201/acute-lymphoblastic-leukemia-therapeutics-market
Amyloidosis Therapeutics Market
The global amyloidosis therapeutics market is valued at approximately $5.3 billion in 2024, with expectations to grow significantly, reaching an estimated $10.8 billion by 2034. This represents a robust Compound Annual Growth Rate (CAGR) of about 7.5% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/51157/amyloidosis-therapeutics-market
Scleroderma Diagnostics Therapeutics Market
The scleroderma diagnostics and therapeutics market is valued at approximately $1.2 billion in 2024, with projections indicating a robust growth trajectory that will elevate the market to around $2.4 billion by 2034. This growth reflects a Compound Annual Growth Rate (CAGR) of 7.4% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/51023/scleroderma-diagnostics-therapeutics-market
U.S. Leukemia Therapeutics Market
The U.S. leukemia therapeutics market is valued at approximately $22 billion, reflecting robust growth driven by advancements in precision medicine, novel drug approvals, and an increasing incidence of leukemia cases. The market is projected to reach nearly $40 billion by 2034, highlighting a significant expansion over the forecast period.
https://exactitudeconsultancy.com/reports/50793/u-s-leukemia-therapeutics-market
Rna Based Therapeutics Market
The RNA-based therapeutics market is projected to reach a value of approximately $7.3 billion in 2024, driven by advancements in mRNA technology and increasing investments in gene therapies. The market is expected to expand significantly with a projected value of around $19.6 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of 10.4% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/50749/rna-based-therapeutics-market
U.S. Antimicrobial Therapeutics Market
The U.S. antimicrobial therapeutics market is valued at approximately $70 billion in 2024, with projections suggesting it will reach around $100 billion by 2034. This represents a Compound Annual Growth Rate (CAGR) of approximately 6% over the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/50709/u-s-antimicrobial-therapeutics-market
U.S. Hereditary Angioedema Therapeutics Market
The U.S. hereditary angioedema (HAE) therapeutics market is valued at approximately $1.6 billion in 2024, with projections estimating it will reach around $4.6 billion by 2034. This growth reflects a robust Compound Annual Growth Rate (CAGR) of about 11.5% from 2025 to 2034.
https://exactitudeconsultancy.com/reports/50587/u-s-hereditary-angioedema-therapeutics-market
Antimicrobial Therapeutics Market
The global antimicrobial therapeutics market is projected to reach approximately $60.5 billion in 2024, driven by increasing antibiotic resistance, rising prevalence of infectious diseases, and an expanding geriatric population. The market is poised for significant growth, with a forecasted value of around $89.2 billion by 2034, reflecting a Compound Annual Growth Rate (CAGR) of approximately 4.0% during the period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/50192/antimicrobial-therapeutics-market
Europe Nucleic Acid Therapeutics Market
The European nucleic acid therapeutics market is valued at approximately €8.5 billion, driven by advancements in mRNA technology and increasing investment in gene therapies. The growing prevalence of genetic disorders and the demand for innovative treatments present significant growth opportunities. Over the forecast period from 2025 to 2034, the market is anticipated to reach about €22 billion, reflecting a robust compound annual growth rate (CAGR) of 9.5%.
https://exactitudeconsultancy.com/reports/50130/europe-nucleic-acid-therapeutics-market
U.S. Nucleic Acid Therapeutics Market
The U.S. nucleic acid therapeutics market is valued at approximately $7.4 billion, driven by advancements in mRNA technologies and a surge in genetic therapies aimed at addressing unmet medical needs. The projected market value is expected to reach $18.6 billion by 2034, reflecting robust growth prospects. This translates to a compound annual growth rate (CAGR) of 9.6% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/50120/u-s-nucleic-acid-therapeutics-market
Hereditary Angioedema Therapeutics Market
The global market for hereditary angioedema (HAE) therapeutics is valued at approximately $3.5 billion in 2024, with projections estimating growth to around $6.2 billion by 2034. This reflects a robust compound annual growth rate (CAGR) of about 6.3% during the forecast period from 2025 to 2034.
https://exactitudeconsultancy.com/reports/50078/hereditary-angioedema-therapeutics-market
Ophthalmic Topical Therapeutics Market
The ophthalmic topical therapeutics market is projected to reach a value of approximately $35 billion in 2024, driven by an increasing prevalence of ocular diseases and a growing aging population. Over the forecast period from 2025 to 2034, the market is expected to grow at a robust Compound Annual Growth Rate (CAGR) of around 6.5%, reaching an estimated value of nearly $63 billion by 2034.
https://exactitudeconsultancy.com/reports/50062/ophthalmic-topical-therapeutics-market
Protein Therapeutics Market
The global protein therapeutics market is valued at approximately $276 billion in 2024, driven by increasing demand for biologics and advancements in biotechnology. The market is projected to reach around $485 billion by 2034, highlighting significant growth during the forecast period. This represents a Compound Annual Growth Rate (CAGR) of about 6.1% from 2025 to 2034.
https://exactitudeconsultancy.com/reports/50037/protein-therapeutics-market
Candidiasis Therapeutics Market
The global market for candidiasis therapeutics is expected to reach a value of approximately $3.2 billion in 2024, showcasing robust growth driven by increasing incidence rates of candidiasis infections, particularly among immunocompromised patients. The market is projected to expand at a compound annual growth rate (CAGR) of 8.5% from 2025 to 2034, reaching an estimated value of around $7.5 billion by the end of the forecast period.
https://exactitudeconsultancy.com/reports/49939/candidiasis-therapeutics-market
Cancer Therapeutics Biotherapeutic Market
The cancer therapeutics biotherapeutic market is valued at approximately $158 billion. This sector is anticipated to demonstrate robust growth, projecting a market value of around $284 billion by 2034, driven by advancements in personalized medicine and immunotherapy. The forecasted period from 2025 to 2034 reflects a compound annual growth rate (CAGR) of 6.2%.
https://exactitudeconsultancy.com/reports/49938/cancer-therapeutics-biotherapeutic-market
Contact Data Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@exactitudeconsultancy.com
